Gene · 4605
Papers2,561
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,561
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer. | Anticancer Drugs | 2026 | 42068974 | PubTator, text mining | PubMed |
| Integrative Machine Learning and Experimental Validation Identify MYBL2 as a Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma. | Oncol Res | 2026 | 42065054 | PubTator, text mining | PubMed |
| Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer. | NPJ Precis Oncol | 2026 | 42049996 | PubTator, text mining | PubMed |
| A Pan-Cancer Transcriptomic Signature for Conserved Molecular Programs Underlying Premalignant-Malignant Progression Across Common Carcinomas. | Dent J (Basel) | 2026 | 42041682 | PubTator, text mining | PubMed |
| Zinc-dependent Zip7-MAZ-MYBL2 axis promotes prostate cancer metastasis. | Commun Biol | 2026 | 42010154 | PubTator, text mining | PubMed |
| Adaptive Regulation of dNTP Homeostasis Confers Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. | Cancer Res | 2026 | 41941751 | PubTator, text mining | PubMed |
| NetCrafter: ontology-derived gene network modeling and functional interpretation. | Brief Bioinform | 2026 | 41921194 | PubTator, text mining | PubMed |
| The role of Notch signalling and its crosstalk with oestrogen receptor signalling in breast cancer. | Cancer Metastasis Rev | 2026 | 41894035 | PubTator, text mining | PubMed |
| The Gut Metabolite Phenylacetylglutamine Inhibits the Angiogenic Potential of Human Umbilical Vein Endothelial Cells Via the β-Adrenergic Receptor-LDHA Axis. | J Cardiovasc Transl Res | 2026 | 41874920 | PubTator, text mining | PubMed |
| HNRNPH1 drives glioblastoma progression by regulating the splicing of cell cycle genes. | Cell Death Dis | 2026 | 41872153 | PubTator, text mining | PubMed |
| The MYBL2-GTSE1 axis promotes laryngeal squamous cell carcinoma progression by regulating PI3K/AKT-dependent glycolytic reprogramming. | Cancer Biol Ther | 2026 | 41866755 | PubTator, text mining | PubMed |
| Omics insights into MYBL2-promoted cancer stem-like cells driving ferroptosis resistance in hepatocellular carcinoma. | J Adv Res | 2026 | 41864611 | PubTator, text mining | PubMed |
| Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review). | Int J Oncol | 2026 | 41860028 | PubTator, text mining | PubMed |
| Molecular mechanism of S100P promotes hepatocellular carcinoma by regulating MYBL2-mediated transcription of AURKB. | Cell Signal | 2026 | 41856224 | PubTator, text mining | PubMed |
| DUSP12 promotes cell cycle progression and protects cells from ZNF622 mediated apoptosis. | Cell Death Dis | 2026 | 41851086 | PubTator, text mining | PubMed |
| Cis-trans divergence in the regulatory architectures of MYBL2 and MYB underlies distinct transcriptional networks in immunometabolic traits. | Comput Biol Chem | 2026 | 41812607 | PubTator, text mining | PubMed |
| Emerging roles of RNA N5-methylcytosine modification in reproductive physiology and gynecological diseases. | Epigenetics | 2026 | 41778387 | PubTator, text mining | PubMed |
| A multi-omics R-loop-linked risk program highlights CKS2-positive proliferative tumor cells as drivers of glioma growth. | Int Immunopharmacol | 2026 | 41763168 | PubTator, text mining | PubMed |
| When Estrogen Signaling Refuses to Die: Receptor Rewiring, Compartmentalization, and Endocrine Plasticity in Gynecological Cancers. | Int J Mol Sci | 2026 | 41752059 | PubTator, text mining | PubMed |
FOXM1 Signaling Network Transcriptionally Upregulates Expression of Proteins Involved in Mitotic Progression to Induce High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer. | Int J Mol Sci | 2026 | 41751958 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4605/papers?page=2